HIV TREATMENT

by UNC Health edited by Lisa Lock, reviewed by Robert Egan  Editors’ notes  The GIST Add as preferred source Credit: Pixabay/CC0 Public Domain A new study published in The Lancet Microbe reports the first twice-yearly injectable HIV treatment regimen—combining lenacapavir, teropavimab, and zinlirvimab—has achieved high rates of viral suppression and demonstrated a favorable safety profile at 26 weeks. Led by Joe Eron, […]

by Lancet edited by Stephanie Baum, reviewed by Robert Egan  Editors’ notes  The GIST Add as preferred source Credit: Unsplash/CC0 Public Domain A new, daily oral tablet that combines two current HIV treatment medications, bictegravir and lenacapavir (BIC/LEN), could effectively replace more complicated HIV treatment regimens used by people living with HIV who are long-term survivors, according to

Enhanced immune cells show promise in targeting viral reservoirs that current medications can’t eliminate Peer-Reviewed PublicationCase Western Reserve University image: Jonathan Karn view more  Credit: Case Western Reserve University CLEVELAND— More than 30 million people with HIV must take antiretroviral therapy (ART) medications daily to keep the virus under control, according to the Joint United Nations Programme